Nan Fung Group Holdings Ltd
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 13, 2026), Nan Fung Group Holdings Ltd reported 27 stock positions worth $111.7 million. Its top holding was Evommune (EVMN) at 22.1% of the portfolio, followed by Maplight Therapeutics (MPLT, 15.3%) and Oculis (OCS, 9.2%). Compared with Q3 2025, it opened 4 new positions, sold out of 1 and reduced 1. The biggest buy was a new position in Evommune (EVMN) and the biggest sale an exit from Joby Aviation (JOBY).
- Most Recent 13F
- Q2 2026
- Location
- KAI TAK, K3
- CIK
- 0001782539
- Portfolio Value
- $111.7M (Q4 2025)
- SEC Filing
- 0001012975-26-000144 ↗ filed Feb 13, 2026
Holdings Value
Holdings 27 stocks · $111.7M
| EVMN Evommune Inc. | 22.08% | 1,441,032 | $24.7M | New |
| MPLT Maplight Therapeutics Inc. | 15.27% | 971,253 | $17.1M | New |
| OCS Oculis Holding AG | 9.20% | 514,702 | $10.3M | No change |
| MDGL Madrigal Pharmaceuticals Inc. | 6.19% | 11,872 | $6.9M | No change |
| LBRX LB Pharmaceuticals Inc. | 5.98% | 300,000 | $6.7M | No change |
| INCY Incyte Corp. | 5.22% | 59,022 | $5.8M | No change |
| RYTM Rhythm Pharmaceuticals Inc. | 4.71% | 49,120 | $5.3M | No change |
| ONC Beone Medicines Ltd.-ADR | 4.28% | 15,722 | $4.8M | No change |
| PCOR Procore Technologies Inc. | 3.47% | 53,299 | $3.9M | New |
| HELP Cybin Inc. | 3.37% | 460,000 | $3.8M | New |
| ASND Ascendis Pharma A/S | 2.60% | 13,600 | $2.9M | No change |
| ACAD Acadia Pharmaceuticals Inc. | 2.46% | 102,984 | $2.8M | No change |
| RXRX Recursion Pharmaceuticals-A | 2.18% | 595,287 | $2.4M | No change |
| LAB Standard Biotools Inc. | 2.16% | 1,883,179 | $2.4M | No change |
| KYMR Kymera Therapeutics Inc. | 2.15% | 30,875 | $2.4M | No change |
| ARGX Argenx SE - ADR | 2.11% | 2,800 | $2.4M | No change |
| RVMD Revolution Medicines Inc. | 1.37% | 19,253 | $1.5M | No change |
| ETHA iShares Ethereum Trust ETF | 1.01% | 50,549 | $1.1M | No change |
| HRMY Harmony Biosciences Holdings | 0.91% | 27,049 | $1.0M | No change |
| IBIT iShares Bitcoin Trust ETF | 0.71% | 15,968 | $793K | No change |
| RANI Rani Therapeutics Holdings Class A | 0.60% | 493,584 | $666K | No change |
| REPL Replimune Group Inc. | 0.55% | 63,719 | $619K | No change |
| TRDA Entrada Therapeutics Inc. | 0.45% | 49,082 | $505K | No change |
| BCYC Bicycle Therapeutics PLC-ADR | 0.44% | 68,943 | $488K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.29% | 58,347 | $319K | No change |
| RKLB Rocket Lab Corp. | 0.24% | 3,824 | $267K | Reduce -87.0% |
| BSLK Bolt Projects Holdings Inc. | 0.03% | 40,597 | $32K | No change |
Portfolio Sells Q3 2025 → Q4 2025
Portfolio Buys Q3 2025 → Q4 2025
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 25 | $131.5M | MPLT, LBRX, EVMN, HELP, INCY |
| Q1 2026 | 24 | $121.3M | EVMN, MPLT, LBRX, OCS, INCY |
| Q4 2025 | 27 | $111.7M | EVMN, MPLT, OCS, MDGL, LBRX |
| Q3 2025 | 24 | $59.6M | OCS, MDGL, ONC, INCY, RYTM |
| Q2 2025 | 20 | $63.4M | HRMY, ILMN, OCS, INCY, ONC |
| Q1 2025 | 35 | $122.6M | HRMY, OCS, ILMN, VRNA, ZLAB |
| Q4 2024 | 35 | $116.9M | ILMN, HRMY, OCS, VRNA, ZLAB |
| Q3 2024 | 38 | $116.1M | ILMN, HRMY, GERN, MRUS, ZLAB |
| Q2 2024 | 44 | $93.7M | ILMN, HRMY, MRUS, GERN, OCS |
| Q1 2024 | 45 | $107.9M | ILMN, HRMY, ALPN, OCS, LAB |